Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -40.87 is 43% above its 5-year average of -71.60, near the high end of its 5-year range (-96.75–-40.87).
44.61% above its 12-month average of -73.79.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -6.68.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-40.87
EARNINGS PER SHARE (EPS) AVG TTM
-73.79
EARNINGS PER SHARE (EPS) AVG 3Y
-78.14
EARNINGS PER SHARE (EPS) AVG 5Y
-71.60
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+44.61%
CURRENT VS 3Y AVG
+47.70%
CURRENT VS 5Y AVG
+42.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Spruce Biosciences, Inc.
Market Cap
$118.90M
Earnings Per Share (EPS)
-40.87
TTM Avg
-73.79
3Y Avg
-78.14
5Y Avg
-71.60
Market Cap
$117.61M
Earnings Per Share (EPS)
N/A
TTM Avg
-5.70
3Y Avg
-9.83
5Y Avg
-0.70
Market Cap
$120.17M
Earnings Per Share (EPS)
-0.53
TTM Avg
-0.95
3Y Avg
-1.58
5Y Avg
-1.49
Market Cap
$119.62M
Earnings Per Share (EPS)
-4.09
TTM Avg
-2.59
3Y Avg
-6.03
5Y Avg
-6.97
Market Cap
$121.51M
Earnings Per Share (EPS)
-1.22
TTM Avg
-1.33
3Y Avg
-1.36
5Y Avg
-1.18
Market Cap
$120.92M
Earnings Per Share (EPS)
-0.28
TTM Avg
-1.88
3Y Avg
-2.46
5Y Avg
-1.80
Market Cap
$115.88M
Earnings Per Share (EPS)
-1.07
TTM Avg
-1.13
3Y Avg
-1.07
5Y Avg
-0.91
Market Cap
$122.13M
Earnings Per Share (EPS)
-1.65
TTM Avg
-6.80
3Y Avg
-14.48
5Y Avg
-27.17
Market Cap
$114.34M
Earnings Per Share (EPS)
-0.89
TTM Avg
-0.91
3Y Avg
-0.79
5Y Avg
-0.74
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spruce Biosciences, Inc. (SPRB) | $118.90M | -40.87 | -73.79 | -78.14 | -71.60 |
| BGM Group Ltd. (BGM)vs › | $117.61M | N/A | -5.70 | -9.83 | -0.70 |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.17M | -0.53 | -0.95 | -1.58 | -1.49 |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.62M | -4.09 | -2.59 | -6.03 | -6.97 |
| Seer, Inc. (SEER)vs › | $121.51M | -1.22 | -1.33 | -1.36 | -1.18 |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | -0.28 | -1.88 | -2.46 | -1.80 |
| Coya Therapeutics, Inc. (COYA)vs › | $115.88M | -1.07 | -1.13 | -1.07 | -0.91 |
| Cibus, Inc. (CBUS)vs › | $122.13M | -1.65 | -6.80 | -14.48 | -27.17 |
| Genelux Corporation (GNLX)vs › | $114.34M | -0.89 | -0.91 | -0.79 | -0.74 |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -0.47 | -0.87 | -1.14 | -0.92 |
Trailing EPS (TTM)
$-40.87
Forward EPS (Est.)
$-25.74
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -50.83 |
| 2024-12-31 | -96.75 |
| 2023-12-31 | -93.00 |
| 2022-12-31 | -72.00 |
| 2021-12-31 | -68.25 |
| 2020-12-31 | -48.75 |
| 2019-12-31 | -22.50 |
| 2018-12-31 | -483.75 |
